Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species

References

• Chinthaginjala H, Kalpana K, Manchikanti SP, Reddy PG, Karamthoy S, Vennapusa NR. Biotherapeutics as drugs, its delivery routes and importance of novel carriers in biotherapeutics. Int J Of Pharma Sci Res. 2021;12:44–19.
   Web of Science ®Google Scholar
• Makurvet FD. Biologics vs. small molecules: drug costs and patient access. Med. Drug Discovery. 2021;9:100075. doi:10.1016/j.medidd.2020.100075.
   Google Scholar
• Ji JA, Zhang B, Cheng W, Wang YJ. Methionine, tryptophan, and histidine oxidation in a model protein, PTH: mechanisms and stabilization. J Pharm Sci. 2009;98(12):4485–500. doi:10.1002/jps.21746.
   PubMed Web of Science ®Google Scholar
• Sreedhara A, Lau K, Li C, Hosken B, Macchi F, Zhan D, Shen A, Steinmann D, Schoneich C, Lentz Y. Role of surface exposed tryptophan as substrate generators for the antibody catalyzed water oxidation pathway. Mol Pharm. 2013;10(1):278–88. doi:10.1021/mp300418r.
   PubMedGoogle Scholar
• Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82(1):47–95. doi:10.1152/physrev.00018.2001.
   PubMed Web of Science ®Google Scholar
• Oliver CN. Inactivation of enzymes and oxidative modification of proteins by stimulated neutrophils. Arch Biochem Biophys. 1987;253(1):62–72. doi:10.1016/0003-9861(87)90637-0.
   PubMed Web of Science ®Google Scholar
• Stadtman ER. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radic Biol Med. 1990;9(4):315–25. doi:10.1016/0891-5849(90)90006-5.
   PubMed Web of Science ®Google Scholar
• Stadtman ER, Oliver CN. Metal-catalyzed oxidation of proteins. Physiological consequences. J Biol Chem. 1991;266(4):2005–08. doi:10.1016/S0021-9258(18)52199-2.
   PubMed Web of Science ®Google Scholar
• Levine RL. Carbonyl modified proteins in cellular regulation, aging, and disease. Free Radic Biol Med. 2002;32(9):790–96. doi:10.1016/S0891-5849(02)00765-7.
   PubMed Web of Science ®Google Scholar
• Chen Y, Doud E, Stone T, Xin L, Hong W, Li Y. Rapid global characterization of immunoglobulin G1 following oxidative stress. MAbs. 2019;11(6):1089–100. doi:10.1080/19420862.2019.1625676.
   PubMed Web of Science ®Google Scholar
• Boll B, Bessa J, Folzer E, Rios Quiroz A, Schmidt R, Bulau P, Finkler C, Mahler HC, Huwyler J, Iglesias A, et al. Extensive chemical modifications in the primary protein structure of Igg1 subvisible particles are necessary for breaking immune tolerance. Mol Pharm. 2017;14(4):1292–99. doi:10.1021/acs.molpharmaceut.6b00816.
   PubMedGoogle Scholar
• Stadtman ER, Levine R. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids. 2004;25:207–18.
   Web of Science ®Google Scholar
• Munir NN, Sangita C, Vikram S. Implications of trace levels of redox-active metals in drug-product formulation. BioPharm International. 2014;27(4).
   Web of Science ®Google Scholar
• Graham RJ, Bhatia H, Yoon S. Consequences of trace metal variability and supplementation on Chinese hamster ovary (CHO) cell culture performance: a review of key mechanisms and considerations. Biotechnol Bioeng. 2019;116(12):3446–56. doi:10.1002/bit.27140.
   PubMed Web of Science ®Google Scholar
• Lam XM, Yang JY, Cleland JL. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci. 1997;86(11):1250–55. doi:10.1021/js970143s.
   PubMed Web of Science ®Google Scholar
• Kohen R, Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol. 2002;30(6):620–50. doi:10.1080/01926230290166724.
   PubMed Web of Science ®Google Scholar
• Torosantucci R, Schoneich C, Jiskoot W. Oxidation of therapeutic proteins and peptides: structural and biological consequences. Pharm Res. 2014;31(3):541–53. doi:10.1007/s11095-013-1199-9.
   PubMed Web of Science ®Google Scholar
• Nassar M, Chandrasekharan S, Sadineni V. Implications of trace levels of redox-active metals in drug-product formulation. BioPharm International. 2014;27(4).
   Web of Science ®Google Scholar
• Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 1994;233:346–57.
   PubMed Web of Science ®Google Scholar
• Stadtman ER. Covalent modification reactions are marking steps in protein turnover. Biochemistry. 1990;29(27):6323–31. doi:10.1021/bi00479a001.
   PubMed Web of Science ®Google Scholar
• Nyström T. Role of oxidative carbonylation in protein quality control and senescence. Embo J. 2005;24(7):1311–17. doi:10.1038/sj.emboj.7600599.
   PubMed Web of Science ®Google Scholar
• Aryal B, Jeong J, Rao VA. Doxorubicin-induced carbonylation and degradation of cardiac myosin binding protein C promote cardiotoxicity. Proc Natl Acad Sci U S A. 2014;111(5):2011–16. doi:10.1073/pnas.1321783111.
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Menendez J, Najbauer J. Autophagy facilitates the development of breast cancer resistance to the Anti-HER2 monoclonal antibody trastuzumab. PLoS ONE. 2009;4(7):e6251. doi:10.1371/journal.pone.0006251.
   PubMed Web of Science ®Google Scholar
• Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ. 2015;22(3):377–88. doi:10.1038/cdd.2014.150.
   PubMed Web of Science ®Google Scholar
• Aryal B, Rao VA, Ahmad A. Specific protein carbonylation in human breast cancer tissue compared to adjacent healthy epithelial tissue. PLoS One. 2018;13(3):e0194164. doi:10.1371/journal.pone.0194164.
   PubMed Web of Science ®Google Scholar
• Kaushik S, Cuervo AM. Autophagy as a cell-repair mechanism: activation of chaperone-mediated autophagy during oxidative stress. Mol Aspects Med. 2006;27(5–6):444–54. doi:10.1016/j.mam.2006.08.007.
   PubMedGoogle Scholar
• Xiong Y, Contento AL, Nguyen PQ, Bassham DC. Degradation of oxidized proteins by autophagy during oxidative stress in Arabidopsis. Plant Physiol. 2007;143(1):291–99. doi:10.1104/pp.106.092106.
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6(4):443–46. doi:10.1038/74704.
   PubMed Web of Science ®Google Scholar
• Glover ZK, Basa L, Moore B, Laurence JS, Sreedhara A. Metal ion interactions with mAbs: part 1. MAbs. 2015;7(5):901–11. doi:10.1080/19420862.2015.1062193.
   PubMed Web of Science ®Google Scholar
• Rathnayaka H, Mozziconacci O, Sreedhara A, Schoneich C. Fragmentation of a monoclonal antibody by peroxotungstate. Pharm Res. 2018;35(11):219. doi:10.1007/s11095-018-2496-0.
   PubMed Web of Science ®Google Scholar
• Mehta S, Flores H, Walters B, Sreedhara A. Metal ion interactions with mabs: part 2. zinc-mediated aggregation of IgG1 monoclonal antibodies. Pharm Res. 2021;38(8):1387–95. doi:10.1007/s11095-021-03089-7.
   PubMed Web of Science ®Google Scholar
• Grewal P, Mallaney M, Lau K, Sreedhara A. Screening methods to identify indole derivatives that protect against reactive oxygen species induced tryptophan oxidation in proteins. Mol Pharm. 2014;11(4):1259–72. doi:10.1021/mp4007375.
   PubMedGoogle Scholar
• Kryndushkin D, Rao VA. Comparative effects of metal-catalyzed oxidizing systems on carbonylation and integrity of therapeutic proteins. Pharm Res. 2016;33(2):526–39. doi:10.1007/s11095-015-1807-y.
   PubMed Web of Science ®Google Scholar
• Narhi LO, Luo Q, Wypych J, Torosantucci R, Hawe A, Fujimori K, Nashed-Samuel Y, Jawa V, Joubert MK, Jiskoot W. Chemical and biophysical characteristics of monoclonal antibody solutions containing aggregates formed during metal catalyzed oxidation. Pharm Res. 2017;34(12):2817–28. doi:10.1007/s11095-017-2262-8.
   PubMed Web of Science ®Google Scholar
• Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Prueksaritanont T, Ionescu R. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol. 2011;48(6–7):860–66. doi:10.1016/j.molimm.2010.12.009.
   PubMed Web of Science ®Google Scholar
• Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev. 2000;32(3–4):307–26. doi:10.1081/DMR-100102336.
   PubMed Web of Science ®Google Scholar
• Yang Y, Mah A, Yuk IH, Grewal PS, Pynn A, Cole W, Gao D, Zhang F, Chen J, Gennaro L, et al. Investigation of metal-catalyzed antibody carbonylation with an improved protein carbonylation assay. J Pharm Sci. 2018;107(10):2570–80. doi:10.1016/j.xphs.2018.06.015.
   PubMed Web of Science ®Google Scholar
• Jacobsen FW, Padaki R, Morris AE, Aldrich TL, Armitage RJ, Allen MJ, Lavallee JC, Arora T. Molecular and functional characterization of cynomolgus monkey IgG Subclasses. Eur. J. Immunol. 2011;186(1):341–49. doi:10.4049/jimmunol.1001685.
   Google Scholar
• Vlasak J, Ionescu R. Fragmentation of monoclonal antibodies. mAbs. 2011;3(3):253–63. doi:10.4161/mabs.3.3.15608.
   PubMed Web of Science ®Google Scholar
• Schasfoort RBM, Abali F, Stojanovic I, Vidarsson G, Terstappen LWMM. Trends in SPR cytometry: advances in label-free detection of cell parameters. Biosensors. 2018;8(4):102. doi:10.3390/bios8040102.
   PubMedGoogle Scholar
• Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl. 2001;752(2):233–45. doi:10.1016/S0378-4347(00)00548-X.
   PubMedGoogle Scholar
• Kelley RF, O’Connell MP, Carter P, Presta L, Eigenbrot C, Covarrubias M, Snedecor B, Bourell JH, Vetterlein D. Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments. Biochemistry. 1992;31(24):5434–41. doi:10.1021/bi00139a003.
   PubMed Web of Science ®Google Scholar
• Regan L. The design of metal-binding sites in proteins. Annu Rev Biophys Biomol Struct. 1993;22:257–87. doi:10.1146/annurev.bb.22.060193.001353.
   PubMedGoogle Scholar
• Baker HM, Anderson BF, Baker EN. Dealing with iron: common structural principles in proteins that transport iron and heme. Proc Natl Acad Sci U S A. 2003;100(7):3579–83. doi:10.1073/pnas.0637295100.
   PubMed Web of Science ®Google Scholar
• Winter WE, Bazydlo LA, Harris NS. The molecular biology of human iron metabolism. Lab Med. 2014;45(2):92–102. doi:10.1309/LMF28S2GIMXNWHMM.
   PubMed Web of Science ®Google Scholar
• Zhou S, Schöneich C, Singh SK. Biologics formulation factors affecting metal leachables from stainless steel. AAPS PharmSciTech. 2011;12(1):411–21. doi:10.1208/s12249-011-9592-3.
   PubMed Web of Science ®Google Scholar
• Li X, Qian P. Identification of an exposure risk to heavy metals from pharmaceutical-grade rubber stoppers. J. Food Drug Anal. 2017;25(3):723–30. doi:10.1016/j.jfda.2016.07.008.
   PubMed Web of Science ®Google Scholar
• Fliszar KA, Walker D, Allain L. Profiling of metal ions leached from pharmaceutical packaging materials. PDA J. Pharm. Sci. Technol. 2006;60:337–42.
   PubMedGoogle Scholar
• Mehta S, Flores H, Walters B, Sreedhara A. Metal ion interactions with mabs: Part 2. Zinc-mediated aggregation of IgG1 monoclonal antibodies. Pharm Res. 2021;38:1387–95.
   PubMed Web of Science ®Google Scholar
• Davies Michael J. Protein oxidation and peroxidation. Biochemical Journal. 2016;473(7):805–25. doi:10.1042/BJ20151227.
   PubMedGoogle Scholar
• Gao X, Ji JA, Veeravalli K, Wang YJ, Zhang T, McGreevy W, Zheng K, Kelley RF, Laird MW, Liu J, et al. Effect of individual Fc methionine oxidation on FcRn binding: met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation. J Pharm Sci. 2015;104(2):368–77. doi:10.1002/jps.24136.
   PubMed Web of Science ®Google Scholar
• Shen FJ, Kwong M, Keck RG, Harris RJ. The application of tert-butylhydroperoxide oxidation to study sites of potential methionine oxidation in a recombinant antibody. Techniques in Protein Chemistry. 1996;7:275–84.
   Google Scholar
• Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem. 1997;272(33):20313–16. doi:10.1074/jbc.272.33.20313.
   PubMed Web of Science ®Google Scholar
• Bee JS, Davis M, Freund E, Carpenter JF, Randolph TW. Aggregation of a monoclonal antibody induced by adsorption to stainless steel. Biotechnol Bioeng. 2010;105(1):121–29. doi:10.1002/bit.22525.
   PubMed Web of Science ®Google Scholar
• Uehara H, Rao VA. Metal-mediated protein oxidation: applications of a modified ELISA-based carbonyl detection assay for complex proteins. Pharm Res. 2015;32(2):691–701. doi:10.1007/s11095-014-1496-y.
   PubMed Web of Science ®Google Scholar
• Yang Y, Mah A, Yuk IH, Grewal PS, Pynn A, Cole W, Gao D, Zhang F, Chen J, Gennaro L, et al. Investigation of metal-catalyzed antibody carbonylation with an improved protein carbonylation assay. J Pharm Sci. 2018;107(10):2570–80.
   PubMed Web of Science ®Google Scholar
• Zheng K, Ren D, Wang YJ, Lilyestrom W, Scherer T, Hong JKY, Ji JA. Monoclonal antibody aggregation associated with free radical induced oxidation. Int J Mol Sci. 2021;22(8):3952. doi:10.3390/ijms22083952.
   PubMed Web of Science ®Google Scholar
• Burkitt W, Domann P, O’Connor G. Conformational changes in oxidatively stressed monoclonal antibodies studied by hydrogen exchange mass spectrometry. Protein Sci. 2010;19(4):826–35. doi:10.1002/pro.362.
   PubMed Web of Science ®Google Scholar
• Beckley NS, Lazzareschi KP, Chih H-W, Sharma VK, Flores HL. Investigation into temperature-induced aggregation of an antibody drug conjugate. Bioconjug Chem. 2013;24(10):1674–83. doi:10.1021/bc400182x.
   PubMed Web of Science ®Google Scholar
• Adem YT, Schwarz KA, Duenas E, Patapoff TW, Galush WJ, Esue O. Auristatin antibody drug conjugate physical instability and the role of drug payload. Bioconjug Chem. 2014;25(4):656–64. doi:10.1021/bc400439x.
   PubMed Web of Science ®Google Scholar
• Acchione M, Kwon H, Jochheim CM, Atkins WM. Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates. MAbs. 2012;4(3):362–72. doi:10.4161/mabs.19449.
   PubMed Web of Science ®Google Scholar
• Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO. Classification and characterization of therapeutic antibody aggregates. J Biol Chem. 2011;286(28):25118–33. doi:10.1074/jbc.M110.160457.
   PubMed Web of Science ®Google Scholar
• Boll B, Bessa J, Folzer E, Ríos Quiroz A, Schmidt R, Bulau P, Finkler C, Mahler HC, Huwyler J, Iglesias A, et al. Extensive chemical modifications in the primary protein structure of Igg1 subvisible particles are necessary for breaking immune tolerance. Mol Pharm. 2017;14(4):1292–99.
   PubMedGoogle Scholar
• Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2009;15(24):7479–91. doi:10.1158/1078-0432.CCR-09-0636.
   PubMed Web of Science ®Google Scholar
• Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res. 2010;70(11):4481–89. doi:10.1158/0008-5472.CAN-09-3704.
   PubMed Web of Science ®Google Scholar
• Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. 2012;2:62. doi:10.3389/fonc.2012.00062.
   PubMedGoogle Scholar
• Nakajima T, Okayama H, Ashizawa M, Noda M, Aoto K, Saito M, Monma T, Ohki S, Shibata M, Takenoshita S, et al. Augmentation of antibody-dependent cellular cytotoxicity with defucosylated monoclonal antibodies in patients with GI-tract cancer. Oncol Lett. 2018;15(2):2604–10. doi:10.3892/ol.2017.7556.
   PubMed Web of Science ®Google Scholar
• Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10(5):301–16. doi:10.1038/nri2761.
   PubMed Web of Science ®Google Scholar
• Jiang X-R, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov. 2011;10(2):101–11. doi:10.1038/nrd3365.
   PubMed Web of Science ®Google Scholar
• Yogo R, Yamaguchi Y, Watanabe H, Yagi H, Satoh T, Nakanishi M, Onitsuka M, Omasa T, Shimada M, Maruno T, et al. The Fab portion of immunoglobulin G contributes to its binding to Fcγ receptor III. Sci Rep. 2019;9(1):11957. doi:10.1038/s41598-019-48323-w.
   PubMedGoogle Scholar
• Sun Y, Izadi S, Callahan M, Deperalta G, Wecksler AT. Antibody–receptor interactions mediate antibody-dependent cellular cytotoxicity. Int. J. Biol. Chem.International. 2021;297(1):100826. doi:10.1016/j.jbc.2021.100826.
   Google Scholar
• Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2018;29(4):917–23. doi:10.1093/annonc/mdy023.
   PubMed Web of Science ®Google Scholar
• Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11(2):263–75. doi:10.1586/era.10.226.
   PubMed Web of Science ®Google Scholar
• Cumnock K, Tully T, Cornell C, Hutchinson M, Gorrell J, Skidmore K, Chen Y, Jacobson F. Trisulfide modification impacts the reduction step in antibody-drug conjugation process. Bioconjug Chem. 2013;24(7):1154–60. doi:10.1021/bc4000299.
   PubMed Web of Science ®Google Scholar
• Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4). doi:10.1042/BSR20150089.
   PubMed Web of Science ®Google Scholar
• Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020;13(1):45. doi:10.1186/s13045-020-00876-4.
   PubMed Web of Science ®Google Scholar
• Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2018;9(1):63–73. doi:10.1007/s13238-017-0473-8.
   PubMed Web of Science ®Google Scholar
• Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol. 1999;29(9):2819–25. doi:10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6.
   PubMed Web of Science ®Google Scholar
• Hensel M, Steurer R, Fichtl J, Elger C, Wedekind F, Petzold A, Schlothauer T, Molhoj M, Reusch D, Bulau P. Identification of potential sites for tryptophan oxidation in recombinant antibodies using tert-butylhydroperoxide and quantitative LC-MS. PLoS One. 2011;6(3):e17708. doi:10.1371/journal.pone.0017708.
   PubMed Web of Science ®Google Scholar
• Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402(6762):672–76. doi:10.1038/45257.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 2005;65(8):3336–46. doi:10.1158/0008-5472.CAN-04-3640.
   PubMed Web of Science ®Google Scholar
• Cao X, Hu X, Zhang X, Gao S, Ding C, Feng Y, Bao W, Permyakov EA. Identification of metal ion binding sites based on amino acid sequences. PLOS ONE. 2017;12(8):e0183756. doi:10.1371/journal.pone.0183756.
   PubMed Web of Science ®Google Scholar
• Zhang J, Fan J, Zeng X, Nie M, Chen W, Wang Y, Luan J, Zhu Z, Chang X, Ju D, et al. Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer. Cell Death Dis. 2021;12(4):288. doi:10.1038/s41419-020-03349-1.
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, Ridgway J, Henner D, Wong W, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Sciences. 1992;89(10):4285–89. doi:10.1073/pnas.89.10.4285.
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51. doi:10.1056/NEJMra043186.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Muela N, Hernández-Pinto AM, Serrano-Puebla A, García-Ledo L, Latorre SH, de la Rosa Ej, Boya P, de la Rosa EJ. Lysosomal membrane permeabilization and autophagy blockade contribute to photoreceptor cell death in a mouse model of retinitis pigmentosa. Cell Death Differ. 2015;22(3):476–87. doi:10.1038/cdd.2014.203.
   PubMed Web of Science ®Google Scholar
• Janser FA, Tschan MP, Langer R. The role of autophagy in HER2-targeted therapy. Swiss Med Wkly. 2019;149:w20138. doi:10.4414/smw.2019.20138.
   PubMed Web of Science ®Google Scholar
• Liu P, Fan J, Wang Z, Zai W, Song P, Li Y, Ju D. The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells. AMB Express. 2020;10(1):107. doi:10.1186/s13568-020-01044-0.
   PubMed Web of Science ®Google Scholar
• Spiridon CI, Guinn S, Vitetta ES. A comparison of the in vitro strong&#x003e; and in vivo activities of IgG and F(ab′)2 fragments of a mixture of three monoclonal anti-her-2 antibodies. J. Exp. Clin. Cancer Res. 2004;10(10):3542–51. doi:10.1158/1078-0432.CCR-03-0549.
   Google Scholar
• Sreedhara A, Lau K, Li C, Hosken B, Macchi F, Zhan D, Shen A, Steinmann D, Schöneich C, Lentz Y. Role of surface exposed tryptophan as substrate generators for the antibody catalyzed water oxidation pathway. Mol Pharm. 2013;10:278–88.
   PubMedGoogle Scholar
• Subelzu N, Schöneich C. Pharmaceutical excipients enhance iron-dependent photo-degradation in pharmaceutical buffers by near UV and visible light: tyrosine modification by reactions of the antioxidant methionine in citrate buffer. Pharm Res. 2021;38(5):915–30. doi:10.1007/s11095-021-03042-8.
   PubMed Web of Science ®Google Scholar
• Garcia NK, Sreedhara A, Deperalta G, Wecksler AT. Optimizing hydroxyl radical footprinting analysis of biotherapeutics using internal standard dosimetry. J Am Soc Mass Spectrom. 2020;31(7):1563–71. doi:10.1021/jasms.0c00146.
   PubMed Web of Science ®Google Scholar
• Uehara H, Rao VA. Metal-mediated protein oxidation: applications of a modified ELISA-based carbonyl detection assay for complex proteins. Pharm Res. 2015;32:691–701.
   PubMed Web of Science ®Google Scholar